Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer
China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...
Clinical trial approval / initiation
Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...
Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...
RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...
Roche and Genprex Initiate Phase I Trial Combining Tecentriq and Reqorsa for ES-SCLC
Switzerland-based Roche (SWX: ROG) is advancing the evaluation of its anti-PD-L1 drug, Tecentriq (atezolizumab), in...
HutchMed’s HMPL-306 Advances to Phase III Trial in R/R AML Patients
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced the commencement of the RAPHAEL study,...
Yunnan Baiyao’s Radiopharmaceutical INR101 Advances to Clinical Trial Stage with NMPA Approval
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...
Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has...
WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light
WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...
RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial
Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...
Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
Laekna’s ActRIIA Monoclonal Antibody LAE102 Gets Green Light from China’s CDE for Obesity Treatment
Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the...
Jiangsu Hengrui Pharmaceuticals Advances HRS-5965 with NMPA Clinical Trial Approval for Glomerular Diseases
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...
Yantai Dongcheng Pharmaceutical’s Radiopharmaceutical 18F-LNC1007 Cleared for Australian Phase I Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...
Sichuan Biokin’s EGFR/HER3 ADC Expands Phase II Clinical Program with NMPA Approval
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese biopharmaceutical company, has received approval from...
Tonghua Dongbao Pharmaceuticals Commences Phase IIa Trial for Dual-Targeted Gout Drug Candidate
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a China-based pharmaceutical company, has announced that the first patient...